Orthologic amends PMA (pre-market approval) for spinal fusion product:
This article was originally published in Clinica
Executive Summary
OrthoLogic has submitted its amended premarket approval (PMA) supplement for its spinal fusion product, the SpinaLogic-1000. This is the second amendment made by the Tempe, Arizona-based company since the original supplement was submitted to the FDA in August last year (see Clinica No 823, p 17). SpinaLogic-1000, which uses OrthoLogic's combined magnetic field technology, is designed to act as an adjunct to spinal fusion surgery and to help stimulate bone fusion.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.